Design, Synthesis, Biological Evaluation and Molecular ... · S1 Design, Synthesis, Biological...

Preview:

Citation preview

S1

Design, Synthesis, Biological Evaluation and Molecular

modeling studies of Novel Quinoline Derivatives Against

Mycobacterium tuberculosis

Ram Shankar Upadhayaya,*,† V. Jaya Kishore, † V. Nageswar Rao, † Vivek Sharma, †,

Shailesh S. Dixit† and Jyoti Chattopadhyaya*,‡

†Institute of Molecular Medicine, Pune 411 057, India and

‡Department of Bioorganic Chemistry, Biomedical Centre, Uppsala University, Sweden

S2

Table T1: Sr. No. Contents Page No.

1 1H-NMR spectra of compound 2 S6

2 13C-NMR spectra of compound 2 S7

3 1H-NMR spectra of compound 3 S8

4 13C-NMR spectra of compound 3 S9

5 1H-NMR spectra of compound 4 S10

6 D2O-NMR spectra of compound 4 S11

7 13C-NMR spectra of compound 4 S12

8 1H-NMR spectra of compound 5 S13

9 D2O-NMR spectra of compound 5 S14

10 13C-NMR spectra of compound 5 S15

11 1H-NMR spectra of compound 6 S16

12 D2O-NMR spectra of compound 6 S17

13 13C-NMR spectra of compound 6 S18

14 DEPT-NMR spectra of compound 6 S19

15 1H-NMR spectra of compound 7 S20

16 D2O-NMR spectra of compound 7 S21

17 13C-NMR spectra of compound 7 S22

18 DEPT-NMR spectra of compound 7 S23

19 1H-NMR spectra of compound 8 S24

20 13C-NMR spectra of compound 8 S25

21 DEPT-NMR spectra of compound 8 S26

22 1H-NMR spectra of compound 9 S27

23 13C-NMR spectra of compound 9 S28

24 DEPT-NMR spectra of compound 9 S29

25 1H-NMR spectra of compound 10 S30

S3

26 13C-NMR spectra of compound 10 S31

27 DEPT-NMR spectra of compound 10 S32

28 1H-NMR spectra of compound 11 S33

29 13C-NMR spectra of compound 11 S34

30 1H-NMR spectra of compound 12 S35

31 13C-NMR spectra of compound 12 S36

32 DEPT-NMR spectra of compound 12 S37

33 1H-NMR spectra of compound 13 S38

34 13C-NMR spectra of compound 13 S39

35 DEPT-NMR spectra of compound 13 S40

36 1H-NMR spectra of compound 14 S41

37 D2O-NMR spectra of compound 14 S42

38 13C-NMR spectra of compound 14 S43

39 DEPT-NMR spectra of compound 14 S44

40 1H-NMR spectra of compound 15 S45

41 13C-NMR spectra of compound 15 S46

42 1H-NMR spectra of compound 16 S47

43 13C-NMR spectra of compound 16 S48

44 1H-NMR spectra of compound 17 S49

45 13C-NMR spectra of compound 17 S50

46 1H-NMR spectra of compound 18 S51

47 D2O-NMR spectra of compound 18 S52

48 13C-NMR spectra of compound 18 S53

49 1H-NMR spectra of compound 19 S54

50 13C-NMR spectra of compound 19 S55

51 DEPT-NMR spectra of compound 19 S56

52 1H-NMR spectra of compound 20 S57

S4

53 13C-NMR spectra of compound 20 S58

54 DEPT-NMR spectra of compound 20 S59

55 1H-NMR spectra of compound 21 S60

56 13C-NMR spectra of compound 21 S61

57 1H-NMR spectra of compound 22 S62

58 D2O-NMR spectra of compound 22 S63

59 13C-NMR spectra of compound 22 S64

60 1H-NMR spectra of compound 23 S65

61 13C-NMR spectra of compound 23 S66

62 DEPT-NMR spectra of compound 23 S67

63 1H-NMR spectra of compound 24 S68

64 13C-NMR spectra of compound 24 S69

65 1H-NMR spectra of compound 25 S70

66 13C-NMR spectra of compound 25 S71

67 DEPT-NMR spectra of compound 25 S72

68 1H-NMR spectra of compound 26 S73

69 13C-NMR spectra of compound 26 S74

70 DEPT-NMR spectra of compound 26 S75

71 1H-NMR spectra of compound 27 S76

72 13C-NMR spectra of compound 27 S77

73 DEPT-NMR spectra of compound 27 S78

74 1H-NMR spectra of compound 28 S79

75 13C-NMR spectra of compound 28 S80

76 DEPT-NMR spectra of compound 28 S81

77 1H-NMR spectra of compound 29 S82

78 13C-NMR spectra of compound 29 S83

79 1H-NMR spectra of compound 30 S84

S5

80 13C-NMR spectra of compound 30 S85

81 DEPT-NMR spectra of compound 30 S86

82 1H-NMR spectra of compound 31 S87

83 13C-NMR spectra of compound 31 S88

84 DEPT-NMR spectra of compound 31 S89

85 Table S1: Forcefield based refinement of DARQ-ATP synthase complex. S90

86 Table S2: Split of AutoDock docking energetics. S91

87 Table S3: Standard Deviation Table S93

S6

Br

NOMe Br

2

S7

Br

NOMe Br

2

S8

N

BrN

O

N

3

S9

N

BrN

O

N

3

S10

N

BrNH

O

N

4

S11

N

BrNH

O

N

4

S12

N

BrNH

O

N

4

S13

N

Br

NHO

N

5

S14

N

Br

NHO

N

5

S15

N

BrNH

O

N

5

S16

O

N

BrNH

O6

S17

O

N

Br

NHO

6

S18

O

N

Br

NHO

6

S19

O

N

BrNH

O6

S20

S

N

Br

NHO

7

S21

S

N

BrNH

O7

S22

S

N

Br

NHO

7

S23

S

N

BrNH

O7

S24

N

Br

N

ON

CF3

8

S25

N

BrN

ON

CF3

8

S26

N

BrN

ON

CF3

8

S27

N

BrN

O9

S28

N

BrN

O9

S29

N

BrN

O9

S30

N

BrN

OO

10

S31

N

BrN

OO

10

S32

N

BrN

OO

10

S33

N

Br

N

ONNN

11

S34

N

BrN

ONNN

11

S35

N

Br

N

O

OO

12

S36

N

BrN

O

OO

12

S37

N

Br

N

O

OO

12

S38

N

Br

N

OO

O

13

S39

N

BrN

OO

O

13

S40

N

Br

N

OO

O

13

S41

N

Br

NHO

N

14

S42

N

BrNH

ON

14

S43

N

BrNH

ON

14

S44

N

BrNH

ON

14

S45

N

Br

O

N

15

S46

N

Br

O

N

15

S47

N

Br

O

NNNO2

16

S48

N

Br

O

NNNO2

16

S49

N

Br

O

NN

17

S50

N

Br

O

NN

17

S51

N

Br

O

NH

OO

18

S52

N

Br

O

NH

OO

18

S53

N

Br

O

NH

OO

18

S54

N

Br

O

OO

19

S55

N

Br

O

OO

19

S56

N

Br

O

OO

19

S57

N

Br

O

OO

20

S58

N

Br

O

OO

20

S59

N

Br

O

OO

20

S60

Br

N

OMe

OOOMe

OMe

21

S61

Br

N

OMe

OOOMe

OMe

21

S62

N

Br

O

OO

OH

O22

S63

N

Br

O

OO

OH

O22

S64

N

Br

O

OO

OH

O22

S65

N

Br

O

OO

NO

O

23

S66

N

Br

O

OO

NO

O

23

S67

N

Br

O

OO

NO

O

23

S68

N

Br

O

OO

NO

O

24

S69

N

Br

O

OO

NO

O

24

S70

N

Br

O

OO

NO

25

S71

N

Br

O

OO

NO

25

S72

N

Br

O

OO

NO

25

S73

N

Br

O

OO

NO

26

S74

N

Br

O

OO

NO

26

S75

N

Br

O

OO

NO

26

S76

N

Br

O

OO

NO

27

S77

N

Br

O

OO

NO

27

S78

N

Br

O

OO

NO

27

S79

N

Br

O

OO

NO

O

28

S80

N

Br

O

OO

NO

O

28

S81

N

Br

O

OO

NO

O

28

S82

N

Br

O

OO

NO

N29

S83

N

Br

O

OO

NO

N29

S84

N

Br

O

OO

NO

N

CF3

30

S85

N

Br

O

OO

NO

N

CF3

30

S86

N

Br

O

OO

NO

N

CF3

30

S87

N

Br

O

OO

NO

N

CF3

31

S88

N

Br

O

OO

NO

N

CF3

31

S89

N

Br

O

OO

NO

N

CF3

31

S90

Table S1 Forcefield based refinem

ent of DA

RQ

-ATP synthase com

plex. D

AR

Q

Interaction Energy (kcal/m

ol) Potential Energy (kcal/m

ol) stereosiom

ers R

S

~ -73

~ -2289 SR

~ -66

~ -2260 SS

~ -72

~ -2260

RR

~ -70

~ -2280

S91

Table S2 Split of A

utoDock docking energetics.

Com

pounds

DA

RQ

3 8

17 18

23/24

------------------------------

RS

RR

SR

SS

I.E. 1

-10.53 -10.0

-10.01 -10.61 -9.1 -9.07

-9.36 -10.61 -12.15

Vdw

2

-9.52 -9.78

-8.95 -10.25 -9.1

-9.07 -9.36

-10.60 -12.15 Elec. 3

-1.01 -0.22

-1.07 -0.36

0 0

0 -0.02

0 1 I.E.: Interm

olecular Energy 2 V

dW: van der W

aals, hydrogen bond and desolvation energy 3 Elec.: Electrostatic Energy

S92

Antim

ycobacterial activity:

All the com

pounds were screened for antim

ycobacterial activity against mycobacterium

tuberculosis by BA

CTEC

460 radiometric m

ethods.

The broth based BA

CTEC

460 TB system

was used for the grow

th of Mycobacteria. In this grow

th system, M

ycobacterium Tuberculosis

H37R

V was grow

n in the C14 labelled substrate in 7H

12 medium

, substrate is utilized by growing m

ycobacteria and 14CO

2 is produced, which

is detected in the form of ‘G

rowth Index’ (G

I), which reflects the rate and am

ount of growth in the m

edium vial. If an antituberculosis drug

will be added to the m

edium vial, it w

ill suppress the growth of the bacteria w

hich is detected by the decrease of the GI values as com

pared to

the control vial. The positive controls taken in the experiment w

ere the standard therapeutic drugs presently used for the treatment of the

tuberculosis, Isoniazid and Rifam

pin.

The rate of increase in GI values or the change in G

I over the previous day GI is called delta (∆) G

I, is compared w

ith that of control values.

If ∆GI of the drug-containing vial is equal to or greater than (≥) than that in control vial the organism

s are considered resistant to the drug. On

the contrary if ∆GI of the drug-containing vial is less (<) than that in control vial the organism

s are considered susceptible.

On the basis of the values calculated for ∆G

, out of all screened compounds, four com

pounds i.e. 3, 8, 17 and 18 were found to act as active

antimycobacterial agents. B

elow given table depicts ∆G

of the compounds tested.

S93

Table S3: Standard Deviation Table

Day

s 1

2 3

4 5

6 7

∆∆∆ ∆ G

I 8

∆∆∆ ∆ G

I 9

∆∆∆ ∆ G

I %

Inhibition

12 22

25 28

34 33

35 02

35 0

56 21

94.4 16

27 32

40 51

49 57

08 47

10 57

10 94.3

G

I 14

24 30

39 48

48 53

05 55

2 61

6 94

N

N

OMe

Br

N

SD

2 2.51

3.6 6.6

9.1 9

11.7

10.1

2.6

0.20 1

1 0

0 0

0 0

0 0

0 0

0 100

1 0

0 0

0 0

0 0

0 0

0 0

100 G

I

1 1

0 0

0 0

0 0

0 0

0 0

100 N

N

OMe

Br

NCF3

SD

0

0.6 0

0 0

0 0

0

0

0

1 0

0 0

0 0

0 0

0 0

0 0

100 9

10 10

10 9

8 9

01 8

1 8

0 99.2

G

I 3

10 11

10 0

7 7

0 7

0 6

-1 99.4

N

N

OMe

Br

N

SD

4.1

5.8 6.1

5.8 5.2

4.3 4.7

4.3

4.2

0.41

23 40

52 67

81 81

95 14

98 3

106 08

89.4 15

27 37

45 52

48 53

05 53

0 55

-2 94.5

G

I 18

34 44

55 63

58 64

06 64

0 64

0 93.6

N

NHOMe

Br

OO

SD

4.0

6.5 7.5

11 14.6

16.9 21.7

23.5

27.2

2.7

12 12

10 9

8 7

5 0

5 -1

4 0

99.6 13

11 11

9 9

8 8

1 7

-2 8

0 99.2

G

I 14

14 12

4 10

8 9

1 9

-1 8

0 99.2

Isoniazid

SD

1 1.52

1 2.9

1 0.57

2.1

2

2.3

0.23 20

48 86

159 290

437 711

6 817

13 903

23

21 49

87 161

288 435

713 9

820 13

945 25

G

I

20 48

86 148

292 439

711 1

815 6

935 21

Control

SD

0.57 0.57

0.57 7

2 2

1.15

2.51

21.9

S94

Recommended